ARDENT HEALTH INCARDT
ASignal's systematic analysis rates ARDT as Neutral.
Reflects the latest available analysis · analyzed Sep 14, 2026
The case on ARDT
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Gross margin of 58.38% indicates strong pricing power
- Forward P/E of 8.76x suggests potential undervaluation relative to earnings expectations
- EV/Revenue of 0.54x indicates possible value at enterprise level
- Positive free cash flow of $208.31M
- Current ratio of 2.10x reflects solid short-term liquidity
- Negative revenue growth of -1.40% year-over-year
- Earnings growth down 77.1% YoY, indicating severe profitability pressure
- High debt-to-equity ratio of 1.30x, above recommended threshold
- MACD histogram negative, signaling weakening momentum
- No Reddit mentions, suggesting lack of retail investor interest
See the full verdict on ARDT
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes ARDT
Most investors never get a second opinion, let alone several. ASignal runs ARDT past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.